Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFS AgroFresh Solutions	$3.00	$2.99	$1.46 ▼ $3.01	$161.16M	1.06	177,103 shs	N/A
DCGO DocGo	$1.52 -3.5%	$1.69	$1.23 ▼ $5.68	$154.50M	0.95	765,941 shs	316,009 shs
GRNA GreenLight Biosciences	$0.30	$0.30	$0.18 ▼ $5.90	$45.43M	1.44	486,986 shs	732 shs
JSPR Jasper Therapeutics	$5.68 +2.3%	$5.20	$3.13 ▼ $26.05	$85.24M	2.72	309,387 shs	72,896 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFS AgroFresh Solutions	0.00%	0.00%	0.00%	0.00%	0.00%
DCGO DocGo	-1.88%	-7.10%	+10.95%	-41.42%	-49.19%
GRNA GreenLight Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
JSPR Jasper Therapeutics	+1.09%	+8.19%	0.00%	+34.06%	-75.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGFS AgroFresh Solutions	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DCGO DocGo	2.4266 of 5 stars	3.3	1.0	0.0	0.0	3.3	2.5	0.6
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	2.2454 of 5 stars	3.5	3.0	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGFS AgroFresh Solutions	0.00	N/A	N/A	N/A
DCGO DocGo	2.50	Moderate Buy	$3.56	134.98% Upside
GRNA GreenLight Biosciences	0.00	N/A	N/A	N/A
JSPR Jasper Therapeutics	3.00	Buy	$59.25	944.05% Upside

Current Analyst Ratings Breakdown

Latest JSPR, DCGO, AGFS, and GRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
5/12/2025	DCGO DocGo	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$5.00 ➝ $1.45
5/9/2025	DCGO DocGo	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/9/2025	DCGO DocGo	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/8/2025	DCGO DocGo	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGFS AgroFresh Solutions	$161.94M	1.00	$0.26 per share	11.40	$3.28 per share	0.91
DCGO DocGo	$616.55M	0.25	$0.40 per share	3.78	$3.09 per share	0.49
GRNA GreenLight Biosciences	$10.20M	4.45	N/A	N/A	$0.32 per share	0.94
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGFS AgroFresh Solutions	-$33.36M	-$0.94	N/A	N/A	N/A	-20.60%	-11.48%	-3.17%	N/A
DCGO DocGo	$19.99M	-$0.02	N/A	18.94	N/A	-0.12%	2.52%	1.70%	8/6/2025 (Estimated)
GRNA GreenLight Biosciences	-$167.05M	-$1.14	N/A	∞	N/A	-1,521.00%	-374.26%	-122.78%	N/A
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)

Latest JSPR, DCGO, AGFS, and GRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	DCGO DocGo	-$0.01	-$0.09	-$0.08	-$0.09	$104.25 million	$96.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGFS AgroFresh Solutions	N/A	N/A	N/A	N/A	N/A
DCGO DocGo	N/A	N/A	N/A	N/A	N/A
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGFS AgroFresh Solutions	1.45	2.39	2.01
DCGO DocGo	N/A	2.44	2.44
GRNA GreenLight Biosciences	0.49	1.21	1.21
JSPR Jasper Therapeutics	N/A	4.31	4.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGFS AgroFresh Solutions	N/A
DCGO DocGo	56.44%
GRNA GreenLight Biosciences	24.41%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
AGFS AgroFresh Solutions	39.40%
DCGO DocGo	2.70%
GRNA GreenLight Biosciences	30.30%
JSPR Jasper Therapeutics	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGFS AgroFresh Solutions	300	53.72 million	32.55 million	Optionable
DCGO DocGo	4,407	101.98 million	99.23 million	Optionable
GRNA GreenLight Biosciences	280	151.68 million	105.72 million	Not Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable

JSPR, DCGO, AGFS, and GRNA Headlines

Recent News About These Companies

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $62.22 Consensus Price Target from Analysts

June 28 at 2:11 AM | americanbankingnews.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Brokerages

June 25, 2025 | marketbeat.com

Jasper Therapeutics stock maintains buy rating on positive urticaria data

June 18, 2025 | investing.com

Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria

June 15, 2025 | nasdaq.com

Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized

June 15, 2025 | investing.com

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

June 14, 2025 | globenewswire.com

Analysts Offer Predictions for JSPR FY2026 Earnings

June 10, 2025 | marketbeat.com

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

June 3, 2025 | globenewswire.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by Brokerages

June 1, 2025 | marketbeat.com

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

May 29, 2025 | finance.yahoo.com

Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential

May 21, 2025 | insidermonkey.com

Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development

May 16, 2025 | nasdaq.com

Jasper Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025 | globenewswire.com

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%

May 6, 2025 | aaii.comA

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%

April 22, 2025 | aaii.comA

Why Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%

April 11, 2025 | aaii.comA

Jasper Therapeutics inks new sales agreement, ends previous deal

March 21, 2025 | uk.investing.com

Jasper Therapeutics files $300M mixed securities shelf

March 19, 2025 | markets.businessinsider.com

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

March 2, 2025 | msn.com

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

March 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, DCGO, AGFS, and GRNA Company Descriptions

AgroFresh Solutions NASDAQ:AGFS

AgroFresh Solutions, Inc. engages in the provision of food preservation and waste reduction solutions for fresh produce. Its products include SmartFreshTM, HarvistaTM, and FreshCloud. It operates through the following segments: AgroFresh Core and AgroFresh Fruit Protection. The AgroFresh Core produces preservation and waste reduction solutions for growers and packers. The AgroFresh Fruit Protection segment offers fungicides, disinfectants and coatings primarily focused on the citrus market. The company was founded on October 24, 2013 and is headquartered in Philadelphia, PA.

DocGo NASDAQ:DCGO

$1.52 -0.06 (-3.50%)

As of 11:30 AM Eastern

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.

GreenLight Biosciences NASDAQ:GRNA

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Jasper Therapeutics NASDAQ:JSPR

$5.68 +0.13 (+2.25%)

As of 11:29 AM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time